2004 Silex commissioned the world’s first silicon laser 2009 Silex announced in June the acquisition of
the Sydney Olympic Park (SOP) solar PV panel manufacturing facility - the only PV panel plant
Translucent secured its first US Patent for ‘optical
silicon’ and filed patents for Silicon -on-Insulator (SOI) and dielectric substrates for the silicon
gLE submitted a license application to the US
nrC to build and operate a commercial SILEX uranium-enrichment facility in Wilmington N.C
In august the nrC announced it had accepted
Translucent wins a US Defence Department
the license application, triggering a ~30 months
DarPa grant to help develop the ‘optical silicon’
technology, under DarPa’s Electronics and Photonics Integrated Circuits (EPIC) Program.
gLE in July announced the on-schedule start-up of the Test Loop to evaluate the next-generation
Subsidiary ChronoLogic wins a Federal government
SILEX uranium enrichment technology.
“Commercial ready grant” for its novel ‘USB-inSyncTM’ Data acquisition technology ($1.2M for three years). 2010 Silex acquired the business assets of Melbourne-
based Solar Systems group (SSG) in March for
$20M. SSG’s concentrating PV technology is
Silex and the General Electric Company sign
applicable to large utility-scale solar power
an exclusive Commercialisation and License
generation, using its unique ultra-high efficiency
agreement for the SILEX Uranium Enrichment
Technology in May, with US Government authorisations received in October.
gLE and Silex announced the successful completion of the Test Loop initial measurement program in april. 2007 Transfer of the SILEX Uranium Enrichment project
to GE’s Wilmington, North Carolina nuclear fuel
The Silex Solar PV Panel manufacturing plant
plant was completed in the first half of 2007.
officially opened at Sydney Olympic Park in April.
Hitachi joined gE as project partner.
In December the company undertook an expansion of the plant to 35MW annual production capacity.
gE-Hitachi Signs Letters of Intent for uranium enrichment services and support using the SILEX
2011 Silex Systems successfully completed a capital
Technology with Exelon and Entergy - the two
raising of $89 million and a share purchase plan
largest nuclear power utilities in the US.
which raised a further $20 million (total capital raised of $109 million).
Silex successfully completes a $50 million capital raising on market in October.
Solar Systems announced in March the commencement of preliminary activities for
2008 global Laser Enrichment (gLE), formed as
construction of a 2MW Pilot Demonstration
a subsidiary of GE Hitachi Nuclear Energy
Facility at Mildura – the precursor to a 100MW
(gEH) to commercialise the SILEX Technology,
Solar Power Station, using its unique ultra-high
announced that it had selected its Wilmington,
efficiency ‘Dense array’ technology.
N.C., headquarters site for the first potential commercial SILEX uranium enrichment facility.
Completion of a $75 million Federal Government funding package for the 100MW Mildura solar power
gLE was notified that the U.S. nuclear regulatory
station was announced by Solar Systems in June. A
Commission (nrC) approved a license to operate
$50 million package from the Victorian Government
the test Loop for the next generation SILEX laser
for the same project was confirmed in 2010.
Silex Solar announced a major restructure of its
GEH and Cameco Corp. (NYSE:CCJ) announced
silicon PV panel business in August, including the
that Cameco Corporation, the world’s largest
shutdown of cell production. This action was required
uranium producer, had joined the gLE venture.
to improve competitiveness in a challenging market.
Cameco paid US$123.8 million for a 24% stake in gLE. gE retained 51% ownership with Hitachi
The US nrC released a revised schedule in
September for the licensing of gLE’s first commercial enrichment production plant using the SILEX Technology. The nrC decision could extend up to six months to Q3 CY 2012.
DOI: 10.1111/j.1468-1293.2008.00664.xHIV Medicine (2009), 10, 152–156Impact of a modified directly administered antiretroviraltreatment intervention on virological outcome inHIV-infected patients treated in Burkina Faso and MaliCM Pirkle,1 C Boileau,2 V-K Nguyen,3 N Machouf,4 S Ag-Aboubacrine,5 PA Niamba,6 J Drabo,7 S Koala,8 C Tremblay9 andS Rashed10,111Unite´ de Sante´ Internationale, Cent